WHAT'S NEW

More

Jul 21, 2015   Notice Concerning Announcement of Results of Phase 3 Clinical Trials of TT-063 Anti-inflammatory Analgesic Patch Formulation Containing S-Flurbiprofen at the Annual Meeting of the Japanese Clinical Orthopaedic Association
Jun 30, 2015   TAISHO AND ABLYNX SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ANTI-TNFα NANOBODY (OZORALIZUMAB) IN JAPAN
May 13, 2015 PDF file Notice of Changes in Board Members and Personnel of the Company and Its Consolidated Subsidiary(Taisho Pharmaceutical Holdings)
Mar 30, 2015 PDF file Signing of Domestic Sales Rights Licensing Agreement Regarding TT-063 Anti-inflammatory Analgesic Patch Formulation Containing S-Flurbiprofen(Taisho Pharmaceutical Holdings)
Mar 30, 2015 PDF file Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate Oral Formulation, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented




Our Company

Page Top

Important Notice Regarding Our Stock

Taisho Pharmaceutical Co., Ltd. incorporated a wholly owning parent company, Taisho Pharmaceutical Holdings Co., Ltd., on October 3, 2011 through a sole-share transfer. Accordingly, information for shareholders and other investors can now be found on the "Investor Relations" section of the Taisho Pharmaceutical Holdings Co., Ltd. website.

"Investor Relations" Taisho Pharmaceutical Holdings Co., Ltd.